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Editors: Anton N. Sidawy and Bruce A. PerlerDurability of the Endurant stent graft in patients
undergoing endovascular abdominal aortic aneurysm
repair
Theodosios Bisdas, MD, Kristin Weiss, MD, Markus Eisenack,
MD, Martin Austermann, MD, Giovanni Torsello, MD, and
Konstantinos P. Donas, MD
Objective: Several studies have conﬁrmed the excellent early
performance of the Endurant (Medtronic Endovascular, Santa
Rosa, Calif) endoprosthesis to treat abdominal aortic aneur-
ysms (AAAs). However, data about the long-term durability of
the device are still lacking.We conducted this prospective two-
center single-arm study to assess the late outcomes of the
endograft in patients undergoing AAA repair.
Methods: An intention-to-treat analysis was performed for
all comers with AAAs who were implanted with an Endurant
endograft between November 2007 and December 2010.
Clinical and radiologic data were prospectively collected and
analyzed. The primary end point was any AAA-related
reintervention. Secondary end points were overall mortal-
ity, aneurysm shrinkage, all types of endoleak, and device-
related complications.
Results: During the study period, 273 patients underwent
implantation of the Endurant stent graft. The median fol-
low-up time for the primary end point was 42 months
(interquartile range, 30.7-50.7). AAA-related reinterventions
were required in 26 patients (10%), resulting in a reinter-
vention-free probability of 93%, 90%, and 87% at 3, 4, and 5
years, respectively. The leading cause for reintervention was
iliac limb occlusion (n = 10). Only one AAA-related death
(0.3%) was reported within an overall mortality of 29% (n =
78). The median aneurysm shrinkage was 9 mm (inter-
quartile range, 3-15). Five type I (2%) and one type III (0.4%)
endoleaks were identiﬁed. No proximal and two distal limb
migrations (1%) were observed.
Conclusions: Our study conﬁrms late durability of the Endur-
ant endoprosthesis for AAA repair, with very encouraging
freedom from reintervention rates and overall outcomes.Results of the endovascular abdominal aortic aneurysm
repair using the Anaconda aortic endograft
Antonio Freyrie,MD, EnricoGallitto,MD,MauroGargiulo,MD,
Gianluca Faggioli, MD, Claudio Bianchini Massoni, MD,
Chiara Mascoli, MD, Rodolfo Pini, MD, and Andrea Stella, MD*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(14)00556-5Objective: The objective of this study was to evaluate early
and late results of the Anaconda aortic endograft (Vascutek,
Terumo, Inchinnan, Scotland) in a single-center experience.
Methods: From September 2005 to March 2012, patients
underwent endovascular aortic repair for infrarenal aortic
aneurysm (AAA) with Anaconda endograft were pro-
spectively enrolled in a dedicated database. Demographic
and aortoiliac morphological data were considered. Pre-
operative planning was based on thoracoabdominal and
pelvic computed tomography angiography. Follow-up
included duplex ultrasound or computed tomography
angiography at 1, 6, an 12 months and yearly thereafter.
Primary end points were technical success, early and late
primary and primary assisted clinical success (CS), overall
and AAA-related survival and freedom from reinterventions.
Secondary end points were endoleaks (ELs), steno-
obstructive iliac leg complications, and AAA shrinkage.
Results: An Anaconda endograft was implanted in 177
patients (male 94%; mean age, 73.3  7.4 years; American
Society of Anesthesiologists class III-IV, 85% and 9%,
respectively). The mean AAA diameter, neck length, and
diameter were 55  9.7 mm, 26.7  10 mm, and 23  2.3
mm, respectively. There was an aortic neck angle >60 in 44
(25%) patients. Iliac angles >90 were observed in 152
(43%) iliac axes. Technical success was 98.9%. Early CS was
96%. Mean follow-up was 33  23.3 months. Late assisted
CS was 97.7%. Survival at 12, 24, and 36 months was 96.4%,
89%, and 86.2%, respectively. There was only one case of
late AAA-related mortality. Freedom from reintervention
was 94%, 92%, and 85% at 12, 24, and 36 months,
respectively. Three (1.7%) conversions occurred during fol-
low-up. There were 14.1% ELs at the completion angiog-
raphy (EL Ia, 1.1%; EL II, 13%). Late ELs were 20.2% (EL Ia,
1.1%; EL Ib, 2.2%; EL II, 16.9%). Iliac leg complications
occurred in 5.6% of the cases. An AAA shrinkage >5 mm was
observed in 130 (73.4%) patients. In 7 (4%) cases there was
an AAA enlargement >5 mm.
Conclusions: Data in our series demonstrate that the Ana-
conda endograft has good early and late results in the
treatment of AAA.Alternative access techniques with thoracic endovascular
aortic repair, open iliac conduit versus endoconduit
technique
Guido H. W. van Bogerijen, MD, David M. Williams, MD,
Jonathan L. Eliason, MD, Narasimham L. Dasika, MD,
G. Michael Deeb, MD, and Himanshu J. Patel, MD
600 AbstractsBackground: Iliac artery endoconduits (ECs) have emerged
as important alternatives to retroperitoneal open iliac
conduits (ROICs) to aid in transfemoral delivery for thoracic
endovascular aortic repair (TEVAR). We present, to our
knowledge, the ﬁrst comparative analysis between these
alternative approaches.
Methods: All patients undergoing TEVAR with either ROIC
(n = 23) or internal EC (n = 16) were identiﬁed. The mean
age of the cohort was 72.4  11.5 years (82.1% female).
Device delivery was accomplished in 100% of cases. The
primary outcome was the presence of iliofemoral compli-
cations, which was deﬁned as: (1) the inability to success-
fully deliver the device into the aorta via the ROIC or EC
approach; (2) rupture, dissection, or thrombosis of the
ipsilateral iliac or femoral artery; and/or (3) retroperitoneal
hematoma requiring exploration and evacuation. Secondary
outcomes were 30-day mortality and rates of limb loss,
claudication, or revascularization.
Results: At a median follow-up of 10.1 months, the inci-
dence of iliofemoral complications was less for the EC
approach compared with the ROIC technique (12.5% vs
26.1%; P = .301). No patients sustained limb loss. Revas-
cularization was performed in two patients after ROIC.
Lower extremity claudication occurred in one patient after
EC. Early mortality was seen in one patient who underwent
EC. Two-year Kaplan-Meier survival for the entire cohort
was 74.4%, and did not differ between groups (ROIC, 78.3%
vs EC, 68.8%; P = .350). Two-year Kaplan-Meier freedom
from limb loss, claudication, or revascularization did not
differ between the two approaches (ROIC, 91.3% vs EC,
93.8%; P = .961).
Conclusions: Results of this early comparative evaluation of
alternative access routes for TEVAR suggest that an EC
approach is safe, effective, and associated with low rates of
early mortality and late iliofemoral complications. In selec-
ted patients, the EC may be considered an appropriate
delivery route for transfemoral TEVAR.Outcomes of carotid endarterectomy versus stenting in
comparable medical risk patients
Emily L. Spangler, MD, MS, Philip P. Goodney, MD, MS,
Andres Schanzer, MD, David H. Stone, MD, Marc L.
Schermerhorn, MD, Richard J. Powell, MD, Jack L.
Cronenwett, MD, and Brian W. Nolan, MD, MS, for the
Vascular Study Group of New England
Objective: In medically high-risk patients the choice
between carotid artery stenting (CAS) and carotid endar-
terectomy (CEA) can be difﬁcult. The purpose of this study
was to compare risk-stratiﬁed outcomes of CAS and CEA.
Methods: Patients who underwent isolated primary CEA (n
= 11,336) or primary CAS (n = 544) at 29 centers in the
Vascular Study Group of New England were analyzed (2003-
2013); patients with previous ipsilateral CEA or CAS, or
concomitant coronary artery bypass graft were excluded. A
medical risk score based on predicted 5-year mortality was
developed for each patient using a Cox proportional hazardsmodel. Patients in the highest risk score quartile were
termed high-risk (vs normal-risk for the other three quar-
tiles). Medically high-risk patients had a 5-year survival of
65% and comprised 23% of CEA and 25% of CAS patients.
Risk-stratiﬁed outcomes were compared within neuro-
logically symptomatic and asymptomatic patients.
Results: Among asymptomatic patients, rates of in-hospital
stroke and/or death were not different between CAS and
CEA in normal and high-risk cohorts, ranging from 0.7% in
normal-risk CEA patients to 1.6% in high-risk CAS patients.
In symptomatic patients, signiﬁcantly worse outcomes were
seen with CAS compared with CEA in normal-risk and high-
risk patients. Normal-risk symptomatic patients had a stroke
or death rate of 1.3% with CEA, but 5.2% with CAS (P < .01).
In high-risk symptomatic patients, the stroke or death rate
was 1.5% with CEA and 9.3% with CAS (P < .01). No sig-
niﬁcant differences were seen between asymptomatic CEA
and CAS within risk strata across secondary outcome
measures of stroke, death, or myocardial infarction, and
ipsilateral stroke, major stroke, or death. However, symp-
tomatic high-risk CAS patients had signiﬁcantly greater rates
of all secondary outcomes compared with CEA except
death, and symptomatic normal-risk CAS patients had only
signiﬁcantly greater rates of death and stroke, death, or
myocardial infarction.
Conclusions: In the Vascular Study Group of New England,
asymptomatic normal- and high-risk patients do equally
well after CEA or CAS. However, normal- and high-risk
symptomatic patients have substantially worse outcomes
with CAS compared with CEA. High medical risk alone might
be an insufﬁcient indication for CAS in symptomatic
patients.Factors associated with surgical site infection after lower
extremity bypass in the Society for Vascular Surgery (SVS)
Vascular Quality Initiative (VQI)
Jeffrey A. Kalish, MD, Alik Farber, MD, Karen Homa, PhD,
Magdiel Trinidad, MD, Adam Beck, MD, Mark G. Davies,
MD, PhD, Larry W. Kraiss, MD, and Jack L. Cronenwett, MD,
on behalf of the Society for Vascular Surgery Patient Safety
Organization Arterial Quality Committee
Background: Surgical site infection (SSI) is a major source of
morbidity after infrainguinal lower extremity bypass (LEB).
This study examines processes of care associated with in-
hospital SSI after LEB and identiﬁes factors that could
potentially be modiﬁed to improve outcomes.
Methods: The Society for Vascular Surgery (SVS) Vascular
Quality Initiative (VQI) registry (2003 to 2012) was queried
to identify in-hospital SSI after 7908 consecutive LEB pro-
cedures performed by 365 surgeons at 91 academic and
community hospitals in 45 states. Variables associated with
SSI were identiﬁed using multivariable logistic regression
and hierarchical clustering. Expected and observed SSI rates
were calculated for each hospital.
Results: The overall in-hospital SSI rate after LEB was 4.8%.
Univariate analysis showed that obesity, dialysis, tissue loss,
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graft conduit, continuous incision for vein harvest, trans-
fusion >2 units of packed red blood cells, procedure time
>220 minutes, and estimated blood loss >100 mL were
associated with higher SSI rates, whereas chlorhexidine
(compared with iodine) skin preparation was protective.
Multivariable analysis showed independent predictors of
SSI included ankle-brachial index <0.35 (odds ratio [OR],
1.53; 95% conﬁdence interval [CI], 1.03-2.30, P < .04),
transfusion >2 units (OR, 3.30; 95% CI, 2.17-5.02; P < .001),
and procedure time >220 minutes (OR, 2.11; 95% CI, 1.05-
4.23; P < .04). Chlorhexidine was protective against SSI (OR,
0.53; 95% CI, 0.35-0.79; P = .002). Stratiﬁed analyses based
on the presence of tissue loss yielded similar results. Across
VQI hospitals, observed SSI rates ranged from 0% to 30%,
whereas expected SSI rates adjusted by the four inde-
pendent predictors ranged from 0% to 7.2%.
Conclusions: In-hospital SSI after LEB varies substantially
across VQI hospitals. Three modiﬁable processes of care
(transfusion rate, procedure time, and type of skin prepa-
ration) were identiﬁed and may be used by hospitals to
reduce SSI rates. This study demonstrates the value of the
SVS VQI detailed shared clinical registry to identify
improvement opportunities directly pertinent to providers
that are not available in typical administrative data sets.Trends and determinants of costs associated with the
inpatient care of diabetic foot ulcers
Caitlin W. Hicks, MD, MS, Shalini Selvarajah, MD, MPH,
Nestoras Mathioudakis, MD, Bruce A. Perler, MD, Julie A.
Freischlag, MD, James H. Black III, MD, and Christopher J.
Abularrage, MD
Objective: The cost of care for diabetic foot ulcers is esti-
mated to be more than $1.5 billion annually. The aim of this
study was to analyze inpatient diabetic foot ulcer cost
changes over time and to identify factors associated with
these costs.
Methods: The Nationwide Inpatient Sample (2005-2010)
was queried using the International Classiﬁcation of Dis-
eases, Ninth Revision codes for a primary diagnosis of foot
ulceration. The primary outcomes were changes in adjusted
total hospital charges and costs over time. Multivariable
analysis was performed to assess relative increases (RIs) in
hospital charges per patient in 2005 vs 2010 adjusting
for demographic characteristics, income, comorbidities
(Charlson Comorbidity Index 3), insurance type, hospital
characteristics, diagnostic imaging, revascularization,
amputation, and length of stay.
Results: Overall, 336,641 patients were admitted with a
primary diagnosis of diabetic foot ulceration (mean age,
62.9  0.1 years, 59% male, 61% white race). The annual
cumulative cost for inpatient treatment of diabetic foot
ulcers increased signiﬁcantly from 2005 to 2010
($578,364,261 vs $790,017,704; P < .001). More patients
were hospitalized (128.6 vs 152.8 per 100,000 hospital-
izations; P < .001), and the mean adjusted cost per patienthospitalization increased signiﬁcantly over time ($11,483 vs
$13,258; P < .001). The proportion of nonelective admis-
sions remained stable (25% vs 23%; P = .32) and there were
no differences in mean hospital length of stay (7.0  0.1
days vs 6.8  0.1 days; P = .22). Minor (17.9% vs 20.6%; P <
.001), but not major amputations (3.9% vs 4.2%; P = .27)
increased over time. Based on multivariable analysis, the
main factors contributing to the escalating cost per patient
hospitalization included increased patient comorbidities
(unadjusted mean difference 2005 vs 2010 $3303 [RI, 1.08]
vs adjusted $15,220 [RI, 1.35]), open revascularization
(unadjusted $15,145 [RI, 1.25] vs adjusted $30,759 [RI,
1.37]), endovascular revascularization (unadjusted $17,662
[RI, 1.29] vs adjusted $28.937 [RI, 1.38]), and minor
amputations (unadjusted $9918 [RI, 1.24] vs adjusted
$18,084 [RI, 1.33]) (P < .001, all).
Conclusions: Hospital charges and costs related to diabetic
foot ulcers have increased signiﬁcantly over time despite
stable hospital length of stay and proportion of emergency
admissions. Risk-adjusted analyses suggest that this change
might be reﬂective of increasing charges associated with a
progressively sicker patient population and attempts at limb
salvage. Despite this, the overall incidence of major
amputations remained stable.Trends and outcomes of endovascular therapy in the
management of civilian vascular injuries
Bernardino C. Branco, MD, Joseph J. DuBose, MD, Luke X.
Zhan, MD, PhD, John D. Hughes, MD, Kay R. Goshima, MD,
Peter Rhee, MD, and Joseph L. Mills Sr, MD
Objective: The rapid evolution of endovascular surgery has
greatly expanded management options for a wide variety of
vascular diseases. Endovascular therapy provides a less
invasive alternative to open surgery for critically ill patients
who have sustained arterial injuries. The purpose of this
study was to evaluate recent trends in the management of
arterial injuries in the United States with speciﬁc reference
to the use of endovascular strategies and to examine the
outcomes of endovascular vs open therapy for the treat-
ment of civilian arterial traumatic injuries.
Methods: A 9-year analysis of the National Trauma Data
Bank was performed to identify all patients who sustained
arterial injuries. Demographics, clinical data, interventions,
and outcomes were extracted. Propensity scores were used
to match endovascular patients to those undergoing open
operation. Patient outcomes were compared according to
treatment approach.
Results: A total of 23,105 patients were available for anal-
ysis. Overall, there was a signiﬁcant increase in the use of
endovascular procedures during 9 years (from 0.3% in 2002
to 9.0% in 2010; P < .001), particularly among blunt trauma
patients (from 0.4% in 2002 to 13.2% in 2010; P < .001).
This increase was noteworthy and dramatic for injuries of
the internal iliac artery (from 8.0% in 2002 to 40.3% in
2010; P < .001), thoracic aorta (from 0.5% in 2002 to 21.9%
in 2010; P < .001), and common/external iliac arteries (from
602 Abstracts0.4% in 2002 to 20.4% in 2010; P < .001). A signiﬁcant
decrease was noted for open procedures (49.1% in 2002 to
45.6%; P < .001), especially for blunt trauma (42.9% in 2002
to 35.8% in 2010; P < .001). There was a stepwise increase
in the proportion of patients managed by endovascular
therapy as the Injury Severity Score increased (highest in
the spectrum Injury Severity Score 31-50). When outcomes
were compared between matched patients who underwent
endovascular and open procedures, patients who under-
went endovascular procedures had signiﬁcantly lower in-
hospital mortality (12.9% vs 22.4%; odds ratio, 0.5; 95%
conﬁdence interval, 0.4-0.6; P < .001). Endovascular
patients also had decreased rates of sepsis (7.5% vs 5.4%;
odds ratio, 0.7; 95% conﬁdence interval, 0.5-0.9; P = .025).
Conclusions: The use of endovascular therapy in the United
States has increased dramatically during the last decade, in
particular among severely injured blunt trauma patients.
Endovascular therapy was associated with improved in-
hospital mortality and lower rates of sepsis.Risk factors and indications for readmission after lower
extremity amputation in the American College of Surgeons
National Surgical Quality Improvement Program
Thomas Curran, MD, Jennifer Q. Zhang, MD, Ruby C. Lo,
MD, Margriet Fokkema, MD, PhD, John C. McCallum, MD,
Dominique B. Buck, MD, Jeremy Darling, BA, and Marc L.
Schermerhorn, MD, FACS
Background: Postoperative readmission, recently identiﬁed
as a marker of hospital quality in the Affordable Care Act, is
associated with increased morbidity, mortality, and health
care costs, yet data on readmission after lower extremityamputation (LEA) are limited. We evaluated risk factors for
readmission and postdischarge adverse events after LEA in
the American College of Surgeons National Surgical Quality
Improvement Program (NSQIP).
Methods: All patients undergoing transmetatarsal (TMA),
below-knee (BKA), or above-knee amputation (AKA) in the
2011-2012 NSQIP were identiﬁed. Independent predis-
charge predictors of 30-day readmission were determined
by multivariable logistic regression. Readmission indication
and reinterventions, available in the 2012 NSQIP only, were
also evaluated.
Results: We identiﬁed 5732 patients undergoing amputa-
tion (TMA, 12%; BKA, 51%; AKA, 37%). Readmission rate
was 18%. Postdischarge mortality rate was 5% (TMA, 2%;
BKA, 3%; AKA, 8%; P < .001). Overall complication rate was
43% (in-hospital, 32%; postdischarge, 11%). Reoperation
was for wound-related complication or additional amputa-
tion in 79% of cases. Independent predictors of readmission
included chronic nursing home residence (odds ratio [OR],
1.3; 95% conﬁdence interval [CI], 1.0-1.7), nonelective sur-
gery (OR, 1.4; 95% CI, 1.1-1.7), prior revascularization/
amputation (OR, 1.4; 95% CI, 1.1-1.7), preoperative con-
gestive heart failure (OR, 1.7; 95% CI, 1.2-2.4), and pre-
operative dialysis (OR, 1.5; 95% CI, 1.2-1.9). Guillotine
amputation (OR, 0.6; 95% CI, 0.4-0.9) and non-home dis-
charge (OR, 0.7; 95% CI, 0.6-1.0) were protective of read-
mission.Wound-related complications accounted for 49% of
readmissions.
Conclusions: Postdischarge morbidity, mortality, and read-
mission are common after LEA. Closer follow-up of high-risk
patients, optimization of medical comorbidities, and aggres-
sive management of wound infection may play a role in
decreasing readmission and postdischarge adverse events.
